Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Study to Evaluate VE-202 in Single and Multi-Dose Cohorts in Healthy Volunteers

X
Trial Profile

A Phase I Study to Evaluate VE-202 in Single and Multi-Dose Cohorts in Healthy Volunteers

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Jul 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs VE 202 (Primary)
  • Indications Inflammatory bowel diseases
  • Focus Adverse reactions; First in man; Pharmacodynamics
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 30 Jun 2021 Results presented in a PureTech Health Media Release.
    • 09 Jun 2020 According to a Vedanta Biosciences media release, more complete study dataset and analyses from this study will be submitted to a peer-reviewed journal.
    • 09 Jun 2020 Preliminary data from two phase I studies of VE202 (n=105) in healthy volunteers, presented in a Vedanta Biosciences media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top